Profile of teriparatide in the management of postmenopausal osteoporosis.
Int J Womens Health
; 2: 37-44, 2010 Aug 09.
Article
en En
| MEDLINE
| ID: mdl-21072295
ABSTRACT
One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A new class of anabolic agents has emerged within the last decade that brought with it a new concept in osteoporosis therapy building new stronger bone rather than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize these new agents, and which patients benefit most. This article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2010
Tipo del documento:
Article